Top in hem/onc: CAR-T for diffuse midline gliomas, new endometrial cancer therapy
Researchers recently presented early data on the efficacy of chimeric antigen receptor T-cell therapy for diffuse midline gliomas during the virtual American Association for Cancer Research Annual Meeting.
The data showed that three of four patients who received the therapy experienced tumor regression and improvement in neurologic symptoms. A review of the findings was the top story in hematology/oncology last week.
Another top story was about the FDA approval of the PD-1 antagonist Jemperli (dostarlimab-gxly, GlaxoSmithKline) for certain patients with endometrial cancer. The treatment can be used for women with mismatch repair-deficient recurrent or advanced disease that progressed on or after a platinum-containing regimen.
Read these and more top stories in hematology/oncology below:
Novel CAR-T shows ‘promising early signs of clinical efficacy’ for diffuse midline gliomas
Three of four patients who received an investigational CAR T-cell therapy for diffuse midline glioma showed tumor regression and improvement in neurologic symptoms, according to early results of a phase 1 study. The research also identified a previously undescribed yet manageable adverse effect of CAR T-cell therapy that may be specific to the targeting of central nervous system solid tumors. Read more.
FDA approves Jemperli for endometrial cancer subset
The FDA granted accelerated approval to dostarlimab-gxly for treatment of certain women with endometrial cancer. Read more.
Researcher develops novel sensor for early detection of ovarian cancer
Mijin Kim, PhD, has been selected to receive a 2021 Marie-Josée Kravis Women in Science Endeavor fellowship grant for her work on a novel sensor technology designed for early detection of ovarian cancer. Read more.
Should ultrashort mental health screening tools be used across oncology practices?
Evidence consistently reveals that patients with cancer are at heightened risk for distress, which can adversely impact their health-related quality of life and plays a role in overall patient survival. However, despite this evidence, psychosocial distress remains underrecognized by oncology clinicians who lack time and desire brief psychosocial assessments rather than lengthy clinical assessment interviews. Read more.
Remote symptom monitoring can ‘close care gaps’ for people with cancer
Technology-enabled symptom monitoring in conjunction with nurse practitioner follow-up provided responsive care to patients with cancer during the COVID-19 pandemic, according to study results. Read more.